gemtuzumab ozogamicin
talacotuzumab
ofatumumab
alemtuzumab
ubenimex
mogamulizumab
antileukemic
lenzilumab
pegaspargase
mercaptopurine
tyrosine kinase inhibitor
lexatumumab
roscovitine
thioguanine
venetoclax
teneliximab
epimmunome
inotuzumab
brentuximab vedotin
tenatumomab
-toxa-
oleclumab
duligotuzumab
milatuzumab
volociximab
immunotoxin
tigatuzumab
conatumumab
asciminib
cytarabine
chemokine
olutasidenib
immunopanning
immunoreceptor
anticytokeratin
indatuximab ravtansine
chemoimmune
afutuzumab
immunologic cytotoxicity
leukolysis
panitumumab
nivolumab
CD8
naptumomab estafenatox
mapatumumab
antinucleosome
immunocyte
antinucleotide
immunocompatible
ticolubant
immunothrombocytopenia
figitumumab
paratope
ponatinib
cytolethal
pamrevlumab
killer cell
pyroptosis
immunocytotoxic
idelalisib
CD8 cell
cytotoxic T cell
CD8 T cell
iratumumab
alnuctamab
killer T cell
IGHV
cytotoxic reaction
tremelimumab
lintuzumab
CD135
immunocamouflage
promyeloleukemia
bavituximab
ivosidenib
matuzumab
caplacizumab
anti-nuclear factor
active immunity
lumiliximab
immunopoietic
leukemogenicity
myocytopathic
tisagenlecleucel
amivantamab
acrixolimab
calicheamicin
506U78
brentuximab
cemiplimab
antileukemia
edrecolomab
inoculation
midostaurin
chloraminophene
acute lymphoblastic leukemia
forodesine
chemosensillum
fraktaline